Drug Profile


Alternative Names: KRP-209; MRZ 2/579

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merz Pharma
  • Developer Forest Laboratories; Kyorin Pharmaceutical; Merz Pharma
  • Class Antidementias; Cyclopentanes; Drug withdrawal therapies; Small molecules
  • Mechanism of Action Nicotinic receptor antagonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Tinnitus
  • Discontinued Alcoholism; Alzheimer's disease; Pain; Pathologic nystagmus

Most Recent Events

  • 06 Nov 2017 Kyorin Pharmaceutical completes a phase II trial for Tinnitus in Japan (PO) (JapicCTI-152984)
  • 16 Mar 2012 Merz terminates phase III trial (long-term study) in Tinnitus in USA, Europe, and Mexico (NCT00827008)
  • 31 Aug 2011 Phase-II clinical trials in Tinnitus in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top